NPM1 mutations are among the most prevalent genetic alterations in adult acute myeloid leukemia (AML), occurring in approximately 30–35% of cases. The NPM1 gene encodes nucleophosmin, a multifunctional protein primarily localized in the nucleolus, where it plays roles in ribosome biogenesis, DNA repair, and regulation of the cell cycle. Monitoring minimal residual disease (MRD) through molecular assays targeting NPM1 transcripts provides a sensitive approach for evaluating therapeutic efficacy and tracking disease dynamics in clinical research studies. The superRCA® NPM1 Mutation Kit RUO is a high-sensitivity molecular assay designed for the quantitative detection of NPM1 mutation allele frequencies, specifically targeting Mut A, Mut B, and Mut D sequence variants in purified DNA samples. Developed for research use only, this kit enables precise measurement of mutant allele frequency (MAF) using flow cytometry, presenting results as a ratio between wild-type and mutant nucleic acid sequences. This assay is optimized for use with the superRCA® Accessory Kit RUO, which provides the necessary enzymes and buffers to support the mutation detection workflow.

* superRCA® is a registered trademark of Rarity Bioscience AB